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A hemodialysis cohort study of protocol- 
based anticoagulation management
S. Lamontagne1,2* , Tinzar Basein3, Binyue Chang3 and Lakshmi Mallela3
Abstract 
Background: Chronic hemodialysis patients frequently require anticoagulation treatment with warfarin for a variety 
of co-morbidities. The optimal method for monitoring and dose adjustment of warfarin-based anticoagulation in this 
population, however, remains unclear. To examine this more closely, we reviewed all hemodialysis patients at a single 
institution on chronic warfarin therapy for a 10-month period prior to and after the institution of a standardized proto-
col for warfarin dose adjustment and monitoring. Anticoagulation efficacy was assessed by time within the therapeu-
tic INR range (TTR), and resource utilization was assessed by the number of weekly INR measurements required for 
monitoring.
Results: We retrospectively analyzed 4481 patient-days of warfarin therapy data (from 25 hemodialysis patients) in 
the pre-protocol timeframe, and 3308 patient-days of warfarin therapy data (from 21 hemodialysis patients) in the 
on-protocol timeframe. Time within the therapeutic INR range (TTR) did not improve with institution of the dosing 
protocol—51.18% using non protocol-based management, and 51.57% using protocol-based management (p 0.73). 
However, overall resource utilization was reduced with institution of protocolized warfarin monitoring—from 1.71 INR 
measurements per patient-week pre-protocol, to 1.20 INR measurements per patient-week (p < 0.0001) post-protocol.
Conclusions: In this single-center study, institution of a standardized dosing protocol in a hemodialysis population 
on chronic warfarin therapy did not improve the rate of on-target anticoagulation, but did result in significantly lower 
resource utilization. We support protocol-based warfarin management in the hemodialysis population, but future 
work should examine the rate of on-target anticoagulation typically achieved in this group.
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Background
Anticoagulation therapy with warfarin is commonly pre-
scribed in hemodialysis patients, likely due to the high 
burden of co-morbidities (atrial fibrillation, thromboem-
bolic disease) necessitating systemic anticoagulation [1]. 
Although the advent of novel oral anticoagulants may 
change the preferred pharmacotherapy for anticoagula-
tion in the general population, none of the newly-avail-
able anticoagulants are approved for use in End-Stage 
Renal Disease (ESRD) and warfarin will likely remain the 
primary oral anticoagulant in this population. Manage-
ment of warfarin-based anticoagulation in hemodialysis 
patients is challenging for several reasons. First, there is 
frequently a shared management between those provid-
ers who draw the labs needed to monitor warfarin effect 
(often done at a patient’s hemodialysis unit) and those 
who prescribe and dose titrate warfarin (often a primary 
care or non-nephrology provider). Secondly, given the rel-
ative ease and availability of blood sampling in patients on 
hemodialysis, there may be an “availability bias” towards 
more frequent lab monitoring and therefore more fre-
quent warfarin dose adjustment in this population.
The optimal means of dose titration for long-term 
warfarin therapy in the general population has been sug-
gested to include a standardized dose adjustment proto-
col, rather than individual provider-determined dosing 
[2]. The optimal means of dose titration in a hemodialysis 
population (via a dose adjustment protocol or individual 
provider-determined dosing) remains unclear [3].
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In this study, we investigated whether the institution of 
a standardized protocol to guide lab monitoring and dose 
adjustment of warfarin therapy would provide better 
anticoagulation efficacy than non-standardized provider-
determined anticoagulation dosing in the hemodialy-
sis population of Berkshire Medical Center (caring for 
an average of 100 chronic hemodialysis outpatients at 
any time). At this dialysis center, dialysis providers both 
obtain labs necessary to monitor chronic warfarin anti-
coagulation as well as make dose adjustments in warfarin 
therapy for all patients on chronic anticoagulation.
Methods
Under IRB approval, we created a standardized warfarin 
dosing protocol (agreed upon by nephrology providers) 
which specified the optimal interval for lab monitoring 
with INR (International Normalized Ratio) as well as 
the appropriate warfarin dose adjustment. Two separate 
protocols were created—one for low-intensity warfarin 
anticoagulation (Fig. 1, for INR target range 2.0–3.0), and 
one for high-intensity warfarin anticoagulation (Fig.  2, 
for INR target range 2.5–3.5). These protocols (Figs. 1, 2) 
were based on similar institutional protocols used for the 
general population.
All dialysis nursing staff were educated in the appro-
priate use of the protocol, including the use of reference 
tables to assist with easy calculation of any necessary war-
farin dose adjustments. Nursing staff was charged with 
implementation of this protocol, such that the major-
ity of dose adjustments were made without nephrology 
provider input. However, at extreme ranges of sub-ther-
apeutic or supra-therapeutic anticoagulation, individual 
provider judgment was the protocol-specified method for 
determining warfarin dose adjustment and subsequent 
lab monitoring.
Pre-protocol (baseline) anticoagulation efficacy data 
was collected for all hemodialysis patients on chronic war-
farin therapy at our institution for the 10-month period 
from January, 2013 to October, 2013. Per institutional 
IRB guidance, informed consent from individual partici-
pants was not required or obtained as only de-identified 
laboratory data was collected and analyzed. Post-protocol 
(intervention) anticoagulation efficacy data was collected 
for the 10-month period of December, 2013–September, 
2014. Our primary outcome was the efficacy of anticoagu-
lation therapy, as defined by time within the therapeutic 
INR range (TTR), and was calculated by the Rosendaal 
method [4]. A secondary outcome was resource utiliza-
tion, as defined by the number of lab assessments (INR 
values), required for anticoagulation management. Statis-
tical significance for the two major outcomes (TTR and 
frequency of INR monitoring) was calculated using a two 
sample percent defective analysis.
As the intention of this study was to assess the efficacy 
of a dosing protocol in chronic anticoagulation manage-
ment—we excluded data from any time period for which 
there was an extended gap (defined as over 14  days) in 
outpatient warfarin monitoring (due to intercurrent hos-
pitalization, missed outpatient dialysis sessions, etc.…). It 
was assumed that during these extended time gaps that 
warfarin therapy could have been stopped and restarted, 
and the time limit was chosen as 14 days as this was the 
longest monitoring interval specified in our warfarin 
management protocol. In situations where interruptions 
Paent
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warfarin 
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and 
decrease 
10%
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with next 
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Fig. 1 Warfarin monitoring and dose adjustment protocol for Target INR 2.0–3.0 Follow up Algorithm
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in outpatient warfarin monitoring were present, the 
pre-interruption and post-interruption time periods 
were analyzed as separate anticoagulation spans. All 
INR measurements were drawn at the start of a dialysis 
session.
Results
We collected 4481 patient-days of warfarin therapy data 
(from 25 hemodialysis patients) in the pre-protocol time-
frame, and 3308 patient-days of warfarin therapy data 
(from 21 hemodialysis patients) in the post-protocol 
timeframe. Patient characteristics for those hemodialysis 
patients included in the pre and post-protocol analyses 
are summarized in Table 1.
Our primary endpoint, the efficacy of anticoagulation 
as defined by TTR, was 51.18% using non-protocolized 
management, and 51.57% using protocol-based man-
agement (p 0.73, Table 2). Our secondary endpoint, the 
number of INR measurements utilized, was 1.71 per 
patient-week using non-protocolized management, and 
1.20 per patient-week using protocol-based management 
(p < 0.0001, Table 2).
Discussion
Chronic warfarin-based anticoagulation is commonly 
prescribed in the hemodialysis population within the 
United States and is likely to remain a common treatment 
in this population in the foreseeable future. In this single-
center hemodialysis population, we achieved a relatively 
low rate of on-target anticoagulation (51%) by institut-
ing a warfarin dosing protocol, and there was no statis-
tically-significant improvement in overall anticoagulation 
efficacy using a protocol-based dosing method versus a 
non-standardized provider-based dosing method.
There are several possible explanations for the lack of 
improved anticoagulation outcomes after the imple-
mentation of a protocol-based dosing method as was 
observed in our study. First, it is possible that our 
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Fig. 2 Warfarin monitoring and dose adjustment protocol for Target INR 2.5–3.5 Follow up Algorithm
Table 1 Patient characteristics for  pre-protocol and  post-
protocol timespan
Pre-protocol Post-protocol
n 25 21
% Male/female 64/36 57/43
Mean age (as of 11/1/2013) ± standard 
deviation
70 ± 14 61 ± 16
ESRD diagnosis
Diabetic nephropathy 9 7
Hypertension 4 3
Polycystic kidney disease 2 2
Glomerulonephritis 2 4
Renal artery stenosis 2 1
Other 6 4
Indication for warfarin
Atrial fibrillation 17 8
DVT/PE 2 5
Mechanical cardiac valve 1 2
Other 5 6
INR target range
2–3 20 17
2.5–3.5 4 3
Other 1 1
Page 4 of 5Lamontagne et al. BMC Res Notes  (2017) 10:66 
primary outcome measure (time within the therapeu-
tic INR range, TTR) was an inaccurate means to assess 
the true rate of on-target anticoagulation. This appears 
unlikely given that measurement of on-target anticoagu-
lation by another statistical methodology—simply the 
percentage of in-range INR measurements—yields very 
similar results (50.5% on-target anticoagulation using 
non-protocolized management, versus 48.4% on-target 
anticoagulation in the protocol-based management strat-
egy). Second, although nursing adherence to the warfarin 
protocol was mandated (by dialysis unit policy) through-
out the study period, dialysis provider adherence was not. 
The majority of warfarin dose adjustments were made 
by nursing staff, but individual provider input was speci-
fied per protocol in the extremes of subtherapeutic or 
supratherapeutic anticoagulation, and decision-making 
in these “non-standardized” situations may have skewed 
the overall benefit of protocol-based management. Third, 
the providers managing warfarin dose adjustments in 
the pre-protocol timeframe have substantial experience 
in doing so, and prior research has shown that provider 
experience in managing warfarin dose adjustments can 
attenuate the benefit of implementation of a dose adjust-
ment protocol [2].
This study did show a substantial benefit of protocol-
based warfarin management in terms of resource uti-
lization, with 30% fewer INR measurements needed to 
achieve a similar anticoagulation efficacy in the protocol-
based management strategy. Further, the use of provider 
time required for dose adjustment was far less utilizing 
a protocol rather than reviewing a patient’s prior warfa-
rin dose schedule and determining a new dose in each 
instance (Additional file 1).
To our knowledge, only one prior study has similarly 
examined the effect of institution of a warfarin dosing 
protocol in a hemodialysis population, and this found 
similar outcomes—no improvement in the rate of ther-
apeutic INR with use of protocol-based dosing, but a 
reduction in INR measurement utilization with use of a 
protocol [3] (Additional file 2).
Our study was underpowered to examine the clinical 
benefit (incidence of thromboembolic stroke, recurrent 
DVT or PE, etc.…) or clinical harm (bleeding complica-
tions) of these two warfarin dosing strategies, however 
TTR has been validated as a surrogate marker for clini-
cal outcomes in the non-dialysis population [5]. Specifi-
cally, prior research has shown that the clinical benefit 
of anticoagulation in atrial fibrillation (a very common 
indication for warfarin therapy in the ESRD population) 
depends very much on achievement of the target INR—
with substantially greater benefit in centers achieving 
TTR >65% versus those who achieve <65% [6]. If the on-
target anticoagulation rate in our study is reflective of the 
typical TTR in the hemodialysis patient population at 
large it could, in part, explain the large degree of uncer-
tainty as to the overall benefit of warfarin anticoagulation 
(especially for stroke prevention in atrial fibrillation) in 
the dialysis population, as compared to the general popu-
lation [7, 8].
Conclusion
This study showed equivalent anticoagulation efficacy but 
significantly lower resource utilization by implementing 
a warfarin dose adjustment protocol in a hemodialysis 
population. We support the use of warfarin dosing pro-
tocols for all providers responsible for managing chronic 
anticoagulation in an ESRD population.
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